Role of heme-oxygenase pathway on vasopressin deficiency during endotoxemic shock-like conditions.
The septic shock is characterized by decrease in median arterial pressure; many researchers have been related a deficiency in vasopressin release during the septic shock. Lipopolysaccharide administration is used to induce septic shock model in animals. We investigated the heme-oxygenase (HO) inhibition during the endotoxemic shock-like conditions. The LPS administration induced a significant decrease in MAP (-15.4 +/- 1.2 mmHg at second hour, -25.8 +/- 8.7 mmHg at fourth hour, and -22.3 +/- 8.6 mmHg at sixth hour) with a concomitant increase in heart rate (486.3 +/- 55.0, 531.8 +/- 53.8, and 510.0 +/- 55.3 bpm, respectively), a significant decrease in diuresis (from 1.1 +/- 0.7 to 0.4 +/- 0.3/100g body weight at fourth hour), and a transitory decrease in body temperature (from 37.0 +/- 0.5 to 35.4 +/- 0.8 degrees C at second hour). An increase in plasma arginine vasopressin (AVP) concentration (from 3.2 +/- 0.9 to 19.0 +/- 5.7 pg/mL at the first hour) occurred in these animals and was present for 2 h after LPS administration, returning close to basal levels thereafter and remaining unchanged until the end of the experiment. When LPS was combined with the i.c.v. administration of HO inhibitor, we observed a sustained increase in plasma AVP concentration, attenuation in the drop of MAP, and increase in antidiuresis induced by LPS treatment. These data suggest that central HO pathway may activate a control mechanism that attenuates AVP secretion during endotoxemia and may consequently regulate the MAP and diuretic output.
Moreto
Viviana
V
Departamento de Enfermagem Geral e Especializada, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
Stabile
Angelita Maria
AM
Antunes-Rodrigues
José
J
Carnio
Evelin Capellari
EC
D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D003905:Deuteroporphyrins / Q000008:administration & dosage / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006419:Heme Oxygenase (Decyclizing) / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007022:Hypotension / Q000209:etiology; D008070:Lipopolysaccharides; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012772:Shock, Septic / Q000150:complications / Q000378:metabolism* / Q000652:urine; D014667:Vasopressins / Q000172:deficiency* / Q000378:metabolism
D003905:Deuteroporphyrins; D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D014667:Vasopressins; D001127:Arginine Vasopressin; C060750:zinc deuteroporphyrin IX 2,4-bis(glycol); D006419:Heme Oxygenase (Decyclizing)